TACTILE SYSTEMS TECHNOLOGY INC 8K

Tactile Systems Technology, Inc. reported stronger Q2 2026 results with higher revenue, margins, and earnings, executed strategic product and distribution initiatives, repurchased shares, and slightly narrowed full-year revenue guidance while maintaining adjusted EBITDA expectations.

On August 10, 2026, Tactile Systems Technology, Inc. reported its financial results for the quarter and six months ended June 30, 2026, highlighting 9% year-over-year revenue growth to $85.7 million, gross margin expansion to 76%, and a rise in quarterly net income to $7.8 million, alongside increased adjusted EBITDA. The company announced several strategic developments, including an exclusive U.S. distribution agreement with ElastiMed, Inc. to distribute the MyoSleeve wearable compression device to Veterans and active-duty service members and their dependents, the commercial launch of its next-generation AffloVest airway clearance system, continued integration of the LymphaTech acquisition, and publication of six‑month clinical trial results for Flexitouch Plus in head and neck cancer-related lymphedema. Tactile also repurchased $5.3 million of its common stock during the quarter, ended June 30, 2026 with $69.9 million in cash and no debt, and modestly narrowed its full‑year 2026 revenue guidance range to $360–$366 million while reaffirming adjusted EBITDA guidance of $49–$51 million, reflecting confidence in its lymphedema product line but a more conservative outlook for airway clearance due to temporary inventory dynamics.

Filing Facts

CIK

1027838

Ticker

-

Form

8K

Source Type

sec

Accession

0001104659-26-093346

Alert Tier

6